J&J May Pay Criminal Fine As Part Of Risperdal Marketing Settlement

The Wall Street Journal reports that pharmaceutical giant, Johnson & Johnson, may pay up to $2.2 billion to settle claims for its Risperdal marketing practices, and the settlement may include a criminal fine of approximately $400 million.  The settlement would allow Johnson & Johnson to continue to sell its products to government programs.  The final sum of the settlement depends on the states that choose to join the settlement.  The claims against Johnson & Johnson stem from its off-label marketing of the anti-psychotic drug.  The deal also settles claims against J&J for other drugs, including Invega, a drug approved for treating mental illness, and its heart failure drug, Natrecor.  The settlement also closes an investigation into kickbacks J&J allegedly made to nursing home [pharmacy operator, Omnicare.

For more information, please see:

Contact one of our

Experienced Attorneys

If you are aware of any person, corporation or entity that you think may be violating the Federal False Claims Act or a State False Claims Act, contact us today.